Oncogeriatric evaluation for elderly patients suffering from metastatic urologic malignancies;Évaluation oncogériatrique du sujet âgé ayant un cancer urologique métastatique

Progres en Urologie

Volumn 18, Issue SUPPL. 7, 2008, Pages

  Neuzillet, Y ^a   Mejean A ^b,c   Lebret, T ^a  

^a FOCH HOSPITAL   (France)

^b LIPADE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Elderly; Evaluation; Onco geriatry; Prostate cancer; Quality of life; Urology

Indexed keywords

AGED; ARTICLE; FEMALE; GERIATRIC ASSESSMENT; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUESTIONNAIRES; UROLOGIC NEOPLASMS;

EID: 57349190592     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)74576-7     Document Type: Article

References (46)

1. Rochon P.A., Katz J.N., Morrow L.A., McGlinchey-Berroth R., Ahlquist M.M., Sarkarati M., and Minaker K.L. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability A prospective comparison of three comorbidity indices. Med Care 34 (1996) 1093-1101
2. Feinstein A.R. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23 (1970) 455-468
3. Fontaine K.R., Redden D.T., Wang C., Westfall A.O., and Allison D.B. Years of life lost due to obesity. JAMA 289 (2003) 187-193
4. Seve P., Sawyer M., Hanson J., Broussolle C., Dumontet C., and Mackey J.R. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a populationbased study. Cancer 106 (2006) 2058-2066
5. Chester J.D., Hall G.H., Forster M., and Protheroe A.S. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treat Rev 30 (2004) 343-358
6. De Groot V., Beckerman H., Lankhorst G.J., and Bouter L.M. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56 (2003) 221-229
7. Linn B.S., Linn M.W., and Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 16 (1968) 622-626
8. Hudon C., Fortin M., and Vanasse A. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. J Clin Epidemiol 58 (2005) 603-608
9. Nagaratnam N., and Gayagay Jr. G. Validation of the Cumulative Illness Rating Scale (CIRS) in hospitalized nonagenarians. Arch Gerontol Geriatr 44 (2007) 29-36
10. Parmelee P.A., Thuras P.D., Katz I.R., and Lawton M.P. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 43 (1995) 130-137
11. Kaplan M.H., and Feinstein A.R. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chronic Dis 27 (1974) 387-404
12. Charlson M.E., Pompei P., Ales K.L., and Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
13. Buntinx F., Niclaes L., Suetens C., Jans B., Mertens R., and van den Akker M. Evaluation of Charlson's comorbidity index in elderly living in nursing homes. J Clin Epidemiol 55 (2002) 1144-1147
14. Harboun M., and Ankri J. Indices de comorbidité : revue de la littérature et application aux études des populations âgées. Rev Epidemiol Sante Publique 49 (2001) 287-298
15. Greenfield S., Apolone G., McNeil B.J., and Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement Comorbidity and outcomes after hip replacement. Med Care 31 (1993) 141-154
16. Stier D.M., Greenfield S., Lubeck D.P., Dukes K.A., Flanders S.C., Henning J.M., Weir J., and Kaplan S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 54 (1999) 424-429
17. Litwin M.S., Greenfield S., Elkin E.P., Lubeck D.P., Broering J.M., and Kaplan S.H. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 109 (2007) 1777-1783
18. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 36 (2000) 453-471
19. Hall W.H., Jani A.B., Ryu J.K., et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 22-30
20. Singh R., and O'Brien T.S. Comorbidity assessment in localized prostate cancer: a review of currently available techniques. Eur Urol 46 (2004) 28-41
21. Albertsen P.C., Fryback D.G., Storer B.E., Kolon T.F., and Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156 (1996) 127-132
22. Imamura K., McKinnon M., Middleton R., and Black N. Reliability of a comorbidity measure: the Index of Co-Existent Disease (ICED). J Clin Epidemiol 50 (1997) 1011-1016
23. Boulos D.L., Groome P.A., Brundage M.D., Siemens D.R., Mackillop W.J., Heaton J.P., Schulze K.M., and Rohland S.L. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 106 (2006) 1804-1814
24. LU-Yao G., Moore D.F., Oleynick J.U., Dipaola R.S., and Yao S.L. Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol 177 (2007) 535-539
25. Négrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., Buclon M., Pérol D., and Lasset C. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13 (2002) 1460-1468
26. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
27. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon- alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
28. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., and Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
29. Saxman S.B., Propert K.J., Einhorn L.H., Crawford E.D., Tannock I., Raghavan D., Loehrer P.J.S.R., and Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
30. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., and Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
31. Dodd P.M., McCaffrey J.A., Herr H., Mazumdar M., Bacik J., Higgins G., Boyle M.G., Scher H.I., and Bajorin D.F. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
32. Saklad M. Grading of patients for surgical procedures. Anesthesiology 2 (1941) 281-284
33. Froehner M., Koch R., Litz R., Heller A., Oehlschlaeger S., and Wirth M.P. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 62 (2003) 698-701
34. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
35. Cohen H.J., Feussner J.R., Weinberger M., et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 346 (2002) 905-912
36. Balducci L., and Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 14 (2000) 221-227
37. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5 (2000) 224-237
38. Droz J.P., and Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 101 (2008) 23-29
39. Balducci L., Cox C.E., Greenberg H., Miguel R.V., Karl R., and Fabri P.J. Management of Cancer in the Older Aged Person. Cancer Control 1 (1994) 132-137
40. Terret C., Albrand G., and Droz J.P. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2 (2004) 236-240
41. Miller D.K., Lewis L.M., Nork M.J., and Morley J.E. Controlled trial of a geriatric case-finding and liaison service in an emergency department. J Am Geriatr Soc 44 (1996) 513-520
42. Fletcher A.E., Price G.M., Ng E.S., et al. Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial. Lancet 364 (2004) 1667-1677
43. Stuck A.E., Egger M., Hammer A., Minder C.E., and Beck J.C. Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. JAMA 287 (2002) 1022-1028
44. Fried L.P., Tangen C.M., Walston J., et al. Cardiovascular Health Study Collaborative Research Group Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 3 (2001) 146-156
45. Folsom A.R., Jacobs Jr. D.R., Caspersen C.J., Gomez-Marin O., and Knudsen J. Test-retest reliability of the Minnesota Leisure Time Physical Activity Questionnaire. J Chronic Dis 39 (1986) 505-511
46. Lee S.J., Lindquist K., Segal M.R., and Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295 7 (2006) 801-808